Multicell Up 70% As Immune Modulation Patent Filed

Multicell Technologies (MCET.OB) shares skyrocket 70% intra-day as the company announced it has filed a key patent covering its immune modulation method for treating cancers.

Currently, Multicell is focusing on treating cancer and other conditions by modulating the immune system. This Provides a platform from which advanced drug candidates can be developed to alter the immune system, and enable disease-specific targeting.

The latest patent filed entitled, "Methods for Tumor Control and Treatment by Loading an Antigen Presenting Cell", covers the company's dsRNA and Toll-like receptor (TLR) technology for fighting malignant tumors in humans.

Multicell's most advanced profram is MCT-125 for Chronic Fatique Syndrome in Multiple sclerosis sufferers, and has successfully completed phase 2 trials.

Other programs include, MCT-175, MCT-275, MCT-465 for relapsing-remitting MS, type 1 diabetes, and pulmonary influenza infections respectfully, and are all in preclinical testing.

Multicell stock is up 70% at $0.45 a share mid-day trading.

_